International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 808 shares, a decline of 89.7% from the August 15th total of 7,881 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 92,036 shares, the days-to-cover ratio is currently 0.0 days.
International Stem Cell Stock Performance
Shares of OTCMKTS:ISCO traded down $0.01 during trading on Friday, reaching $0.35. The stock had a trading volume of 34,002 shares, compared to its average volume of 30,380. The stock has a market cap of $2.84 million and a price-to-earnings ratio of -4.44. International Stem Cell has a 52 week low of $0.12 and a 52 week high of $0.54. The firm’s fifty day moving average is $0.32 and its 200 day moving average is $0.22.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.01) EPS for the quarter. The business had revenue of $2.67 million for the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
See Also
- Five stocks we like better than International Stem Cell
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
